Navigation Links
Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
Date:9/19/2013

MENLO PARK, Calif., Sept. 19, 2013 /PRNewswire/ -- Protagonist Therapeutics today announced the addition of $4 million to its previously announced Series B private financing, bringing the total raised in this round to $18 million. Pharmstandard International S.A., a holding company of the major pharmaceutical company in Russia, OJSC Pharmstandard (LSE: PHST), has joined the round as a new investor.

(Logo: http://photos.prnewswire.com/prnh/20130501/MM06086LOGO)

"Protagonist's orally stable peptides represent a game-changing approach that especially enables the development of orally administered NCEs (new chemical entities) for inflammatory bowel diseases and other gastro-intestinal disorders," said Alexander Shuster, Ph.D., President of Inbio Ventures, a management company representing Pharmstandard International. "We were impressed by the company's technology, partnerships, development achievements to date, and the management team."

"The addition of Pharmstandard to our investor base reflects the growing international interest in the field of orally active peptides, as well as recognition by investors of the significant advantages offered by our technology over other approaches," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics. "This additional international investment enables us to further focus efforts on building a strong pipeline of developmental candidates for our internal pipeline and selective asset-based partnering."

About Pharmstandard International S.A./Inbio Ventures

Pharmstandard International S.A. – a holding company fully committed by OJSC Pharmstandard (LSE:PHST) – is a venture investments fund focused on innovative drugs/therapies with strong potential at global markets and in Russia and CIS countries. Inbio Ventures is a management company representing Pharmstandard International, S.A., and providing professional support in venture transactions. http://www.inbio-ventures.com.

About Protagonist Therapeutics

Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of 'orally stable peptides' against validated targets and diseases that are currently being addressed only by 'injectable biologics'.  Oral peptides can offer a superior choice to patients, physicians, and payers by virtue of their enhanced safety & efficacy, better convenience & compliance, and favorable affordability in comparison to the injectable antibodies. The company has a proprietary and validated technology platform comprised of well integrated computational, phage display and peptide chemistry discovery tools that are tailored to explore the full potential of oral peptide therapeutics.

Protagonist is a spin-out of University of Queensland's Institute of Molecular Biosciences (IMB) and is headquartered in the USA with discovery operations in Menlo Park, California USA and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.


'/>"/>
SOURCE Protagonist Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
2. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
3. Adheron Therapeutics Names New Senior Leadership
4. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
5. Echo Therapeutics Sends Response to Shareholder Letter
6. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
7. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
8. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
9. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
10. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
11. Oncology Therapeutics Market in India to 2018 Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):